Valuation: Immuneering Corporation

Market Cap 308M 270M 249M 233M 437M 29.05B 446M 2.99B 1.16B 14.36B 1.16B 1.13B 49.79B P/E 2026 *
-4.19x
P/E 2027 * -3.56x
Enterprise Value 308M 270M 249M 233M 437M 29.05B 446M 2.99B 1.16B 14.36B 1.16B 1.13B 49.79B EV / Sales 2026 *
-
EV / Sales 2027 * 19.2x
Free-Float
86.52%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immuneering Corporation

1 day+5.08%
1 week+7.94%
Current month-17.50%
1 month-10.78%
3 months-4.03%
6 months-29.27%
Current year-27.66%
1 week 4.37
Extreme 4.37
4.8
1 month 3.86
Extreme 3.86
5.84
Current year 3.86
Extreme 3.86
8.48
1 year 2.9
Extreme 2.9
10.08
3 years 1
Extreme 1
11.06
5 years 1
Extreme 1
33.99
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 2008-01-31
Director of Finance/CFO 42 2022-08-09
Chief Tech/Sci/R&D Officer - 2023-07-31
Director TitleAgeSince
Chairman 81 2007-12-31
Director/Board Member 44 2008-01-31
Director/Board Member 72 2021-04-26
Date Insider Type Main position Quantity % Market Cap.
06-22Buy

Founder

2,400 0.0037%
06-14Buy

Chief Technology Officer

6,035 0.0093%
06-10Free

Director

33,350 0.0515%
Change 5-day change 1-year change 3-year change Capi.($)
+5.08%+7.94%+34.84%-50.16% 308M
+0.33%+1.37%+63.66%+126.38% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-13.83% 23.07B
-1.04%+7.91%+3.91%+417.68% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+186.30% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average +0.61%+5.09%+41.63%+110.50% 22.66B
Weighted average by Cap. +0.27%+5.14%+48.48%+122.43%

Financials

2026 *2027 *
Net sales - 16M 14.03M 12.93M 12.11M 22.7M 1.51B 23.17M 155M 60.14M 746M 60.08M 58.77M 2.59B
Net income -77.34M -67.81M -62.51M -58.52M -110M -7.3B -112M -751M -291M -3.61B -290M -284M -12.5B -93.9M -82.33M -75.89M -71.05M -133M -8.86B -136M -912M -353M -4.38B -353M -345M -15.18B
Net Debt - -
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
55
Date Price Change Volume
26-06-26 US$4.760 +5.08% 8,407,499
26-06-25 US$4.530 -1.52% 970,570
26-06-24 US$4.600 +1.32% 1,299,679
26-06-23 US$4.540 +2.25% 936,200
26-06-22 US$4.440 +0.68% 1,070,662
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.760USD
Average target price
17.00USD
Spread / Average Target
+257.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMRX Stock